In light of litifilimab recently receiving FDA Breakthrough Therapy Designation for CLE, we spoke with experts to discuss diagnostic and treatment gaps in disease management.

Phase 3 trial data show that obinutuzumab significantly reduces disease activity in very active extrarenal lupus.

Johnson & Johnson's nipocalimab has been granted U.S. Food and Drug Administration Fast Track designation as a potential ...

Objective Biologics for systemic lupus erythematosus (SLE) demonstrate variable treatment responses across trials. We evaluated baseline biomarkers as predictors of response to guide personalised ...

Alumis (NASDAQ:ALMS) executives highlighted recent clinical progress for the company’s TYK2 inhibitor programs and previewed multiple upcoming catalysts during remarks at the Leerink Partners Global ...

It wasn't that long ago that Rachel Dib, a North Carolina mother of three children, was so sick with lupus she struggled to get out of bed to care for ...

This is the largest real-world analysis of mycophenolic acid in pediatric lupus nephritis to date, providing a decision-support system to help balance efficacy and safety.

For the millions of people living with lupus – a chronic autoimmune disease that can damage the kidneys, brain and other ...

Amgen’s bad luck in lupus may finally be coming to an end. Daxdilimab, a monoclonal antibody acquired from Horizon Therapeutics in 2023, hit the primary endpoint in a phase 2 trial for discoid lupus ...

The U.S. Food and Drug Administration (FDA) approved Gazyva® to treat adults with lupus nephritis in October 2025. Gazyva targets and removes harmful B cells to help protect the kidneys in people with ...

Hydroxychloroquine is linked with serious adverse effects, most notably retinopathy, with long-term use, but nevertheless the drug is the mainstay of treatment for lupus. This study examined risks for ...